NNENE EGBE-TAMBE: Open Payments
NPI 1417541194 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$875 in 57 payments from 8 companies in 2025. Trend: 2023 $946 · 2024 $1,306 · 2025 $875
Food & beverage: $875
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 21 | $181 |
| ABBVIE INC. | 12 | $174 |
| Janssen Pharmaceuticals, Inc | 7 | $164 |
| E.R. Squibb & Sons, L.L.C. | 6 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Alkermes, Inc. | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
Products named: Qelbree, VRAYLAR, COBENFY, INVEGA SUSTENNA, CAPLYTA, ABILIFY MAINTENA, ARISTADA, SPRAVATO.
Industry payments across TX — which companies pay providers there.
